Physician profile

Erroll I Byer

Obstetrics & Gynecology · Brooklyn, NY

NPI 1689682437

$452.85

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$30.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $199.70 2022-2023 Veozah
Lupin INC. $59.28 2019
Abbvie INC. $43.31 2020
Coopersurgical, INC. $38.65 2019-2022
Roche Diagnostics Corporation $25.84 2019
Evofem Biosciences, INC. $21.06 2021
Aspira Women'S Health INC $18.31 2022
Glaxosmithkline, LLC. $18.04 2019
Ge Healthcare $16.73 2024
Merck Sharp & Dohme LLC $11.93 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Erroll I Byer

$452.85

in general payments reported 2019-2025

Years
2019-2024
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/1037834/erroll-i-byer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.